|
PTAR1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63258295771129E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.95929988584021E-11 |
| Normal-vs-Stage2 |
1.82660000014323E-07 |
| Normal-vs-Stage3 |
2.83106871279415E-14 |
| Normal-vs-Stage4 |
5.147660075977E-12 |
| Stage1-vs-Stage2 |
5.855400E-01 |
| Stage1-vs-Stage3 |
7.758000E-03 |
| Stage1-vs-Stage4 |
5.761800E-03 |
| Stage2-vs-Stage3 |
1.748410E-01 |
| Stage2-vs-Stage4 |
6.820100E-02 |
| Stage3-vs-Stage4 |
4.417400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.59792187762287E-14 |
| Normal-vs-AfricanAmerican |
3.53309999999718E-05 |
| Normal-vs-Asian |
1.17529999998922E-06 |
| Caucasian-vs-AfricanAmerican |
8.560400E-01 |
| Caucasian-vs-Asian |
3.916000E-01 |
| AfricanAmerican-vs-Asian |
6.949200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.3170354523927E-13 |
| Normal-vs-Female |
2.14528395048319E-12 |
| Male-vs-Female |
3.667200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.48910003719516E-09 |
| Normal-vs-Age(41-60Yrs) |
2.71893618730701E-13 |
| Normal-vs-Age(61-80Yrs) |
3.19011483895792E-12 |
| Normal-vs-Age(81-100Yrs) |
2.443300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.638300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.159700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.876780E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.244000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.434800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.347800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.961400E-04 |
| Classical-VS-Follicular |
2.252000E-01 |
| Classical-VS-Other |
5.604200E-01 |
| Classical-VS-Normal |
9.69024860353329E-12 |
| Tall-VS-Follicular |
3.104100E-02 |
| Tall-VS-Other |
3.306200E-01 |
| Tall-VS-Normal |
7.63711316409399E-12 |
| Follicular-VS-Other |
8.799600E-01 |
| Follicular-VS-Normal |
2.3157999962109E-09 |
| Other-VS-Normal |
5.156900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.76447745303676E-12 |
| Normal-vs-N1 |
1.77519998700859E-09 |
| N0-vs-N1 |
6.690200E-01 |
|
|
